Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7412821 | 1.00 | KMT2A (0.41) | KMT2AALDH1A1MEN1TDP1XBP1 | |
| SCHEMBL6154518 | 0.85 | KMT2A (0.40) | KMT2AALDH1A1MEN1TDP1XBP1 | |
| SCHEMBL323735 | 0.83 | KMT2A (0.45) | KMT2AALDH1A1MEN1TDP1CA1 | |
| SCHEMBL1990105 | 0.83 | KMT2A (0.45) | KMT2AALDH1A1MEN1TDP1CA1 | |
| SCHEMBL323736 | 0.83 | KMT2A (0.45) | KMT2AALDH1A1MEN1TDP1CA1 | |
| SCHEMBL29364700 | 0.83 | KMT2A (0.45) | KMT2AALDH1A1MEN1TDP1CA1 | |
| SCHEMBL2081536 | 0.81 | KMT2A (0.47) | KMT2AALDH1A1MEN1CA1CA2 | |
| SCHEMBL2325747 | 0.81 | KMT2A (0.47) | KMT2AALDH1A1MEN1CA1CA2 | |
| SCHEMBL7587366 | 0.81 | KMT2A (0.47) | KMT2AALDH1A1MEN1CA1CA2 | |
| SCHEMBL28602090 | 0.81 | KMT2A (0.39) | KMT2AALDH1A1MEN1TDP1XBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| US-5015641-A | Dipeptide for vision defects | ANDREWS DAVID R (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0236307-B1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4885293-A | CARBOXYALKYL DIPEPTIDES | SCHERING CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0195817-B1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1989-10-18 | — | — | EP | disclosed |
| US-4840772-A | KIT WITH CONTAINERS OF AGENT TO REDUCE INTRAOCULAR PRESSURE AND ANTIINFLAMMATORY STEROID OR BETA-BLOCKER | SCHERING CORPORATION (US) | 1989-06-20 | — | — | US | disclosed |
| US-4826816-A | Antihypertensive compounds | SCHERING CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| US-4783444-A | SUBSTITUTED DIPEPTIDES | SCHERING CORPORATION (US) | 1988-11-08 | — | — | US | disclosed |
| EP-0236307-A1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS. | SCHERING CORP (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4691049-A | Process for preparing a specific diastereomer of a monoamino dicarboxylic acid ester | SCHERING CORPORATION (US) | 1987-09-01 | — | — | US | disclosed |
| WO-1987001707-A1 | ANTIHYPERTENSIVE AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THE PREPARATION OF THE AGENTS AND COMPOSITIONS | SCHERING CORPORATION (US) | 1987-03-26 | — | — | WO | disclosed |
| US-4634698-A | TOPICAL HYPOTENSIVES | SCHERING CORPORATION (US) | 1987-01-06 | — | — | US | disclosed |
| EP-0195817-A1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SCHERING CORP (US) | 1986-10-01 | — | — | EP | disclosed |
| US-4584285-A | Antihypertensive agents | SCHERING CORPORATION (US) | 1986-04-22 | — | — | US | disclosed |
| WO-1986001803-A1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1986-03-27 | — | — | WO | disclosed |
| US-4556655-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND GLAUCOMA | SCHERING CORPORATION (US) | 1985-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | KMT2A 2974/4885ALDH1A1 944/4885MEN1 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.